Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Goodbye CFDA, Hello MRA: China Overhauls Regulatory Bodies

Executive Summary

China proposes to merge its top drug regulator into new combined body, and creates a medical reimbursement agency in move viewed as sign of strengthening regulatory oversight.

You may also be interested in...



Bigger, Bolder, SMAR: Decoding China's All-In-One Regulatory Agency

A new era began April 10 with disappearance of China FDA and kickoff of State Administration for Market Regulation (SMAR), the so-called 'One-Stop' regulatory agency. Will the CFDA's innovation-encouraging policies continue? How will the new agency balance innovation and enforcement? Pink Sheet offers preliminary answers to these key questions and decode the new SMAR from five important aspects.

CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global

While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.

China's mRNA Shot Shows Benefits Over Older COVID Vaccines

Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.

Topics

Latest News
UsernamePublicRestriction

Register

PS122699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel